Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials
- 1 April 2001
- Vol. 57 (4), 124-128
- https://doi.org/10.1016/s0090-4295(00)00955-9
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- THE PROSTATE: MR IMAGING AND SPECTROSCOPY: Present and FutureRadiologic Clinics of North America, 2000
- Prostate Cancer: Localization with Three-dimensional Proton MR Spectroscopic Imaging—Clinicopathologic StudyRadiology, 1999
- Prostate Cancer: Prediction of Extracapsular Extension with Endorectal MR Imaging and Three-dimensional Proton MR Spectroscopic ImagingRadiology, 1999
- Detection of locally recurrent prostate cancer after cryosurgery: Evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopyUrology, 1996
- Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.Radiology, 1996
- Can aggressive prostatic carcinomas be identified and can their natural history be altered by treatment?Urology, 1995
- The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinomaVirchows Archiv, 1995
- Chemoprevention of prostate cancer: Guidelines for possible intervention strategiesJournal of Cellular Biochemistry, 1992
- When is intervention warranted?Journal of Cellular Biochemistry, 1992
- Unsuspected Adenocarcinoma of the Prostate in Patients Undergoing Cystoprostatectomy for other Causes: Incidence, Histology and Morphometric ObservationsJournal of Urology, 1989